Mr. Tetsuomi Takano, President and CEO, t2T Healthcare Inc., was invited to the 16th DIA China Annual Meeting 2024 in Suzhou on 16-19 May 2024 as a clinical development and regulatory expert from Japan.
He introduced some latest trend in clinical development methods and regulatory environments, e.g. DCT (Decentralized Clinical Trials) and AI (Artificial Intelligence), and disussed with US-FDA, EMA, Johnson & Johnson Global Regulatory VP, AstraZeneca Global Regulatory VP, Roche China Regulatory Head, and Fortrea Global Regulatory Head at a workshop titled “Hot Topics in Global Regulatory Affairs” on Fri, 17 May.
